Determining the Subjective and Physiological Effects of BZP on Human Females

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2009 Sep 25

PMID 19777213

Citations 10

Authors

Joanne C Lin

Nisha Bangs

Heeseung Lee

Rob R Kydd

Bruce R Russell

Affiliations

Soon will be listed here.

Abstract

Background: "Party pills" containing benzylpiperazine (BZP) used to be widely and legally available as recreational drugs in New Zealand. There are only two published trials on human subjects (1973), which suggested that 100 mg of BZP produced subjective and physiological effects similar to 10 mg of dexamphetamine. The purpose of this study is to further investigate the subjective and physiological responses to BZP in females.

Methods/study Design: In a randomised, double blind, placebo-controlled study, the subjective and physiological effects of BZP were investigated in 27 healthy, right-handed non-smoking females (mean age 22 +/- 3 years). Two groups were tested before and approximately 120 minutes after administration of a single oral dose of either 200 mg BZP (n = 14) or placebo (n = 13). Participants were required to comment on the subjective effects of BZP using three rating scales-the Addiction Centre for Research Inventory, the Profile of Mood States and the Visual Analogue Scale. Participants' blood pressure, heart rate and temperature were also measured.

Results/findings: Statistical analysis using a split-plot analysis of variance and t tests revealed that BZP significantly increases blood pressure and heart rate (p < 0.05) Likewise, the subjective reports revealed that BZP has significant stimulant effects, increases euphoria and dysphoria and increases sociability and drug liking (p < 0.05).

Discussion/interpretation: Physiological and subjective data reflected a clear similarity between the effects of BZP and those of other commonly known stimulants such as amphetamine and 3,4-methylenedioxymethamphetamine.

Citing Articles

Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: a single-dose study.

Lee H, Wang G, Curley L, Sollers J, Kydd R, Kirk I Psychopharmacology (Berl). 2015; 233(5):863-71.

PMID: 26630992 DOI: 10.1007/s00213-015-4165-x.

Psychoactive Substances Bill and Act of New Zealand: A Chance to Engage Undergraduate Scientists with Society using a Transfer Learning Paradigm.

Gliddon C, Cridge B J Undergrad Neurosci Educ. 2015; 14(1):A1-7.

PMID: 26557790 PMC: 4640477.

Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.

Curley L, Kydd R, Robertson M, Pillai A, McNair N, Lee H Psychopharmacology (Berl). 2015; 232(16):2969-80.

PMID: 25893641 DOI: 10.1007/s00213-015-3933-y.

Abuse liability of novel 'legal high' designer stimulants: evidence from animal models.

Watterson L, Watterson E, Olive M Behav Pharmacol. 2013; 24(5-6):341-55.

PMID: 23839028 PMC: 6661301. DOI: 10.1097/FBP.0b013e3283641ec8.

Differential responses to anticipation of reward after an acute dose of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) alone and in combination using functional magnetic resonance imaging (fMRI).

Curley L, Kydd R, Kirk I, Russell B Psychopharmacology (Berl). 2013; 229(4):673-85.

PMID: 23666554 DOI: 10.1007/s00213-013-3128-3.

References

Staack R, Fritschi G, Maurer H . Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 773(1):35-46. DOI: 10.1016/s1570-0232(01)00619-5. View

Fleckenstein A, Wilkins D, GIBB J, Hanson G . Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther. 1997; 283(1):281-5. View

Terner J, de Wit H . Menstrual cycle phase and responses to drugs of abuse in humans. Drug Alcohol Depend. 2006; 84(1):1-13. DOI: 10.1016/j.drugalcdep.2005.12.007. View

Lavian G, Di Bona G, Finberg J . Inhibition of sympathetic nerve activity by acute administration of the tricyclic antidepressant desipramine. Eur J Pharmacol. 1991; 194(2-3):153-9. DOI: 10.1016/0014-2999(91)90099-c. View

Evans S . The role of estradiol and progesterone in modulating the subjective effects of stimulants in humans. Exp Clin Psychopharmacol. 2007; 15(5):418-26. DOI: 10.1037/1064-1297.15.5.418. View

Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K . Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm. 1987; 39(2):203-11. View

Martin W, SLOAN J, SAPIRA J, Jasinski D . Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971; 12(2):245-58. DOI: 10.1002/cpt1971122part1245. View

Foltin R, FISCHMAN M . Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend. 1991; 28(1):3-48. DOI: 10.1016/0376-8716(91)90052-z. View

Murphy M, Antia U, Chang H, Han J, Ibrahim U, Tingle M . Party pills and drug-drug interactions. N Z Med J. 2009; 122(1293):3564. View

10.

Choi S, Jonak E, Simpson L, Patil V, Fernstrom J . Intermittent, chronic fenfluramine administration to rats repeatedly suppresses food intake despite substantial brain serotonin reductions. Brain Res. 2002; 928(1-2):30-9. DOI: 10.1016/s0006-8993(01)03330-3. View

11.

Rivera R, Yacobson I, Grimes D . The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999; 181(5 Pt 1):1263-9. DOI: 10.1016/s0002-9378(99)70120-1. View

12.

Koob G . Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992; 654:171-91. DOI: 10.1111/j.1749-6632.1992.tb25966.x. View

13.

FISCHMAN M, Schuster C, Hatano Y . A comparison of the subjective and cardiovascular effects of cocaine and lidocaine in humans. Pharmacol Biochem Behav. 1983; 18(1):123-7. DOI: 10.1016/0091-3057(83)90261-7. View

14.

Campbell H, Cline W, Evans M, Lloyd J, Peck A . Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol. 1973; 6(3):170-6. DOI: 10.1007/BF00558281. View

15.

Cami J, Farre M, Mas M, Roset P, Poudevida S, Mas A . Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000; 20(4):455-66. DOI: 10.1097/00004714-200008000-00010. View

16.

Cadet J, Brannock C . Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998; 32(2):117-31. DOI: 10.1016/s0197-0186(97)00031-4. View

17.

Tancer M, Johanson C . Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend. 2003; 72(1):33-44. DOI: 10.1016/s0376-8716(03)00172-8. View

18.

Cryan J, Harkin A, Naughton M, Kelly J, Leonard B . Characterization of D-fenfluramine-induced hypothermia: evidence for multiple sites of action. Eur J Pharmacol. 2000; 390(3):275-85. DOI: 10.1016/s0014-2999(00)00012-1. View

19.

Kuo D . Involvement of hypothalamic neuropeptide Y in regulating the amphetamine-induced appetite suppression in streptozotocin diabetic rats. Regul Pept. 2005; 127(1-3):19-26. DOI: 10.1016/j.regpep.2004.10.008. View

20.

White R, STANDEN O . Piperazine in the treatment of threadworms in children; report on a clinical trial. Br Med J. 1953; 2(4839):755-7. PMC: 2029560. DOI: 10.1136/bmj.2.4839.755. View